Floatz logo

Polatuzumab Vedotin

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hoffmann-La Rocheantibody_drug_conjugatePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 1/2CCC
cc-5013
Hoffmann-La Roche
Phase 1/2CCC
DEXAMETHASONE
Hoffmann-La Roche
Phase 1/2CCC
Obinutuzumab
Hoffmann-La Roche
Phase 1/2CCC

Same molecule, other indications

Polatuzumab Vedotin is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Large B-Cell Lymphoma (LBCL)Dormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →